Sales of Non-opioid Pain Patches Surge as Opioid Counterparts Face Intense Scrutiny; FMI Anticipates Logistical Delays Due to COVID-19 Pandemic

Future Market Insights (FMI), Dubai: The non-opioid pain patches market surpassed revenues worth US$ 3.1 Bn in 2019,
witnessing a surge of 3.2% from that recorded in 2018. A detailed study by
Future Market Insights (FMI) forecasts near- and long-term growth outlook of
the non-opioid pain patches market. 2020 will be a challenging year for the
market, as the COVID-19 outbreak has brought medical supplies on the spotlight.

Non-narcotic pain
management solution has been gaining significant momentum, as it does not
involve the risk of addiction as with opioid drug patches such as fentanyl
patches, thereby offering tailwinds to the market growth. However, a headwind
from factory closures and supply chain disruptions triggered by rapid spread of
coronavirus across major regions has been showing fragility of access to
non-opioid pain patches.

Lidocaine Patches to Capture Over 2/3rd
of Total Revenue

Lidocaine patches
continue to account for major share (69%) of manufacturers’ bottom lines, owing
to their extended period of pain management with reduced risk for systemic side
effects and drug interactions. These patches are also recommended as first-line
therapy for the management of neuropathic pain in older patients.

Download Sample Copy with Table of Content:

“Studies indicated that the initial presenting
symptoms of COVID-19 infection, especially among elder patients with
neuropathic pain as a comorbid, could be delayed or worsened by prescribed
transdermal opioid patches. In such cases, demand for non-opioid pain patches
is expected to move on an upward swing,”

the FMI analyst

North America Takes the Lead, MEA to Witness
Relatively Low Adoption

North America will continue
to retain its dominance in the global non-opioid pain patches market,
accounting for 58% of the total value in 2019. In North America, opioid-based
patches for transdermal pain management are facing intense scrutiny during the
COVID-19 pandemic, as they may induce potential immune suppression. With health
care providers turning to better alternatives, growth prospects of the market
are expected to remain high in the region.

Adoption of
non-opioid pain patches in Middle East & Africa will continue to remain stagnant,
due to low product awareness among patients. Moreover, a wide availability of
low-cost, alternative treatments in low-income countries emerges as a key
challenge for the market players.

As per the FMI study, the global non-opioid pain
patches market is set to experience a CAGR of 4% over the forecast period
Gain access to
FMI’s exclusive COVID-19 tracker here

Source: Future
Market Insights

FMI Blog

Leave a Reply

Your email address will not be published. Required fields are marked *